Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab reduction or discontinuation in non-infectious uveitis
NCT05155592Phase 2Unknown
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in noninfectious uveitis (NIU). Primary endpoint: Relapse rate of inflammation at 24 months. Status: unknown.
02
Drugs
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT05155592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155592.